Boston Scientific Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Boston Scientific Corp Unternehmen

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Boston Scientific Corp Informationen



BörsenkürzelBSX

Name des UnternehmensBoston Scientific Corp

IPO-datumMay 19, 1992

CEOMahoney (Michael F)

Anzahl der mitarbeiter53000

WertpapierartOrdinary Share

GeschäftsjahresendeMay 19

Addresse300 Boston Scientific Way

StadtMARLBOROUGH

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl01752-1234

Telefon15086834000

Websitehttps://www.bostonscientific.com/en-US/Home.html

BörsenkürzelBSX

IPO-datumMay 19, 1992

CEOMahoney (Michael F)

Führungskräfte von Boston Scientific Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

1.75M

-58824.00%

Mr. John E. Sununu

Independent Director

54.72K

+2081.00%

Mr. David S. (Dave) Wichmann

Independent Director

41.58K

+2081.00%

Mr. Jonathan R. Monson

Chief Financial Officer, Executive Vice President

35.29K

+562.00%

Mr. Vance R. Brown

Senior Vice President, General Counsel, Corporate Secretary

33.45K

+2084.00%

Ms. Ellen M. Zane

Independent Director

24.13K

-12891.00%

Mr. David C. Habiger

Independent Director

5.63K

+2081.00%

Mr. Yoshiaki Fujimori

Independent Director

2.08K

-2901.00%

Mr. Joseph M. Fitzgerald

Executive Vice President, Group President - Cardiology

--

Mr. Edward J. Ludwig

Lead Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

1.75M

-58824.00%

Mr. John E. Sununu

Independent Director

54.72K

+2081.00%

Mr. David S. (Dave) Wichmann

Independent Director

41.58K

+2081.00%

Mr. Jonathan R. Monson

Chief Financial Officer, Executive Vice President

35.29K

+562.00%

Mr. Vance R. Brown

Senior Vice President, General Counsel, Corporate Secretary

33.45K

+2084.00%

Ms. Ellen M. Zane

Independent Director

24.13K

-12891.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Endoscopy

747.00M

14.75%

Peripheral Interventions

702.00M

13.86%

Urology

682.00M

13.46%

Electrophysiology

607.00M

11.98%

Watchman

470.00M

9.28%

Andere

1.86B

36.66%

Nach RegionUSD

Name

Umsatz

Anteil

United States

3.29B

65.03%

Asia Pacific

802.00M

15.83%

EMEA (Europe, Middle East and Africa)

793.00M

15.66%

Latin America and Canada

175.00M

3.46%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Endoscopy

747.00M

14.75%

Peripheral Interventions

702.00M

13.86%

Urology

682.00M

13.46%

Electrophysiology

607.00M

11.98%

Watchman

470.00M

9.28%

Andere

1.86B

36.66%

Aktionärsstatistik

Aktualisiert: Sat, Nov 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.37%

Fidelity Management & Research Company LLC

6.11%

BlackRock Institutional Trust Company, N.A.

5.37%

State Street Investment Management (US)

4.38%

PRIMECAP Management Company

2.23%

Andere

72.54%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.37%

Fidelity Management & Research Company LLC

6.11%

BlackRock Institutional Trust Company, N.A.

5.37%

State Street Investment Management (US)

4.38%

PRIMECAP Management Company

2.23%

Andere

72.54%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

50.87%

Investment Advisor/Hedge Fund

29.04%

Hedge Fund

4.91%

Pension Fund

2.94%

Research Firm

2.73%

Bank and Trust

1.89%

Sovereign Wealth Fund

1.58%

Family Office

0.23%

Private Equity

0.18%

Andere

5.62%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

2858

1.40B

94.34%

-402.85K

2025Q3

2905

1.40B

94.56%

+9.92M

2025Q2

2818

1.39B

94.08%

+7.87M

2025Q1

2724

1.38B

93.98%

-8.23M

2024Q4

2559

1.38B

93.68%

+12.79M

2024Q3

2401

1.36B

94.13%

-3.01M

2024Q2

2325

1.37B

94.20%

+2.64M

2024Q1

2212

1.37B

95.15%

-32.63M

2023Q4

2153

1.38B

96.34%

-8.17M

2023Q3

2083

1.39B

95.41%

+17.41M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

137.57M

9.28%

+1.09M

+0.80%

Sep 30, 2025

Fidelity Management & Research Company LLC

90.62M

6.11%

-8.85M

-8.90%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

79.60M

5.37%

+1.41M

+1.81%

Sep 30, 2025

State Street Investment Management (US)

64.93M

4.38%

-266.30K

-0.41%

Sep 30, 2025

PRIMECAP Management Company

33.10M

2.23%

-1.56M

-4.50%

Sep 30, 2025

Geode Capital Management, L.L.C.

32.69M

2.21%

+265.55K

+0.82%

Sep 30, 2025

Capital World Investors

26.65M

1.8%

-1.88M

-6.58%

Sep 30, 2025

Managed Account Advisors LLC

23.16M

1.56%

+1.11M

+5.03%

Sep 30, 2025

The Bollard Group, LLC

19.73M

1.33%

-345.87K

-1.72%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

19.46M

1.31%

-275.11K

-1.39%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Dec 1

Name

Anteil

iShares U.S. Medical Devices ETF

12.15%

Goldman Sachs Future Health Care Equity ETF

8.33%

Invesco Dorsey Wright Healthcare Momentum ETF

3.87%

Tema Heart & Health ETF

3.66%

First Trust Bloomberg R&D Leaders ETF

3.14%

Parnassus Core Select ETF

3.1%

WisdomTree US AI Enhanced Value Fund

3.1%

Health Care Select Sector SPDR Fund

3.06%

Global X Aging Population ETF

2.99%

Proshares Ultra Health Care

2.95%

iShares U.S. Medical Devices ETF

Anteil12.15%

Goldman Sachs Future Health Care Equity ETF

Anteil8.33%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil3.87%

Tema Heart & Health ETF

Anteil3.66%

First Trust Bloomberg R&D Leaders ETF

Anteil3.14%

Parnassus Core Select ETF

Anteil3.1%

WisdomTree US AI Enhanced Value Fund

Anteil3.1%

Health Care Select Sector SPDR Fund

Anteil3.06%

Global X Aging Population ETF

Anteil2.99%

Proshares Ultra Health Care

Anteil2.95%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten